Technology transfer / Localization · Latin America · Announced 21 Oct 2026
Samsung Bioepis → Bahiafarma
Samsung Bioepis signed a 10-year Productive Development Partnership with Brazil's state lab Bahiafarma and Bionovis to supply its eculizumab biosimilar SB12 to the SUS from 2027, with manufacturing transferred to the partners over time.
Parties: Samsung Bioepis (South Korea) → Bahiafarma (Brazil)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Brazil — supply to the public health system (SUS) under a Productive Development Partnership
- Therapeutic area
- Rare / Orphan
- Asset
- SB12 (eculizumab)
- Announced
- 21 Oct 2026
Our analysis
Why this matters
Samsung Bioepis announced on 21 October 2026 a 10-year agreement to supply SB12, its biosimilar of eculizumab (reference product Soliris), to Brazil's public health system (SUS) starting in 2027. The deal is structured as a Productive Development Partnership (PDP) with two Brazilian partners: Bahiafarma, a state-level public laboratory, and Bionovis, a local pharmaceutical company. Samsung Bioepis supplies finished product at first, and manufacturing responsibilities move gradually to the Brazilian partners. No contract value was disclosed.
The company cites IQVIA data showing Brazilian public spending on eculizumab exceeded BRL 947 million (about US$171 million) in 2025. ANVISA approved SB12 as a Soliris biosimilar in December 2024 for PNH and aHUS.
The full analysis is free to read with a work email on this page.
Source: Pharma Manufacturing